Market cap
$10.2m
End-of-day close multiplied by current shares on issue.
RUA · NZX
Rua Bioscience is an NZX-listed healthcare / medicinal cannabis company with HY22 - HY26 of published result briefings.
Snapshot
HY26, released 27 February 2026
| Metric | Value | Change |
|---|---|---|
| Revenue | $1.3m | ↑ +7747.1% |
| Operating profit | -$1.7m | ↑ +84.9% |
| NPAT | -$1.8m | ↑ +83.5% |
| Operating cash flow | -$1.5m | ↑ +28.7% |
| OCF / Operating profit % | 92.0% | ↑ +72.5pp |
| Net debt | -$0.4m | ↑ +50.5% |
| Net debt / Operating profit | 0.24x | ↑ +242.9% |
| ROE % | -59.3% | ↑ +55.2pp |
| PBT | -$1.8m | ↑ +83.5% |
| Debtor days | 51 | — |
Source: latest published briefing (HY26, released 27 February 2026). Change compares against the prior equivalent period: HY24, released 29 February 2024.
Valuation
A compact read on what the market price implies next to the latest filing data. The numbers are a starting point for comparison, not a recommendation.
The latest close and share count context for the market price.
Market cap
$10.2m
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
Not available
Not available for this company right now.
EPS
Not available
Not available for this company right now.
PEG
Not available
Not available for this company right now.
EV/EBITDA
Not available
Not available for this company right now.
P/FCF
Not available
Not available for this company right now.
P/B
1.74x
Market value compared with latest reported equity.
Yield and fund-style valuation where the company shape supports it.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Daily closes use the full available width, with hover and touch readouts against real observations. Expand opens the chart at reading size.
Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.
Chat
Ask follow-up questions about Rua Bioscience's latest result and company history.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Longitudinal view
The latest period is shown first.
| Metric | HY266 MONTHS27 February 2026 | FY2512 MONTHS1 September 2025 | HY246 MONTHS29 February 2024 | FY2312 MONTHS29 August 2023 | HY236 MONTHS28 February 2023 | FY2212 MONTHS29 August 2022 | HY226 MONTHS25 February 2022 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3m | $1.9m | $0.02m | $6.5m | $0.25m | $0.65m | $360m | Chart |
| Revenue growth % | 92.2% | 490.6% | -100.0% | 910.8% | -29.4% | 43.2% | 33.8% | Chart |
| Operating profit | -$1.7m | -$3.3m | -$10.9m | -$6.1m | $0.63m | -$7.6m | -$3.9m | Chart |
| Operating profit margin % | -123.8% | -173.6% | n/m | -94.0% | 248.0% | n/m | -1.1% | Chart |
| PBT | -$1.8m | -$3.5m | -$10.9m | -$6m | $0.7m | -$7.5m | -$3.5m | Chart |
| NPAT | -$1.8m | -$3.5m | -$10.9m | -$6m | $0.7m | -$8.6m | -$2.5m | Chart |
| Operating cash flow | -$1.5m | -$2.8m | -$2.1m | -$5.9m | -$3.7m | -$6.8m | -$3.7m | Chart |
| OCF / Operating profit % | 92.0% | 84.5% | 19.5% | 96.4% | -581.6% | 90.3% | 96.1% | Chart |
| FCF pre-lease | — | -$2.8m | -$2.1m | -$6m | -$3.7m | -$7.2m | -$4m | Chart |
| FCF post-lease | — | -$2.8m | — | -$6m | — | — | — | Chart |
| DPS | — | — | 0.0c | — | — | — | — | — |
| ROE % | -59.3% | -70.6% | -114.5% | -29.6% | 2.7%Outside range high roe. 2.7%; 3-period range -114.5% to -9.3%. ROE: 2.7%, above normal range; 3-period mean -61.0%, range -114.5%--9.3%. | -32.6% | -9.3% | Chart
|
| Net debt | -$0.4m | $0.48m | -$0.8m | — | — | -$1.9m | -$2.3m | Chart |
| Net debt / Operating profit | 0.24x | -0.15x | 0.07x | — | — | 0.25x | 0.58x | Chart |
| Debtor days | 51 | 41 | — | 6 | — | — | — | Chart |
| Inventory days | 93 | 78 | 5346 | 1 | 198 | 124 | 0 | Chart |
| Total assets | $8.7m | $6.8m | $10m | $21m | $29.1m | $33.6m | $28m | Chart |
Reference: annolyse.ai/companies/rua
Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.
These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.
Reported revenue across covered periods.
Like-period revenue growth where comparable.
Company-specific earnings measure where disclosed.
EBITDA-equivalent margin where revenue and earnings are source-backed.
Statutory profit after tax.
Cash generated from operations.
Additional verified filing metrics for this company. Each point links back to a published briefing period in the source data contract.
Cash conversion against earnings.
Operating cash flow less capex before leases.
Free cash flow after lease payments where available.
Return on equity.
Borrowings less cash; negative values indicate net cash.
Leverage ratio, suppressed where earnings are not meaningful.
Dividend per share declared for the period.
Receivables days where the working-capital inputs are source-backed.
Inventory days where the working-capital inputs are source-backed.
Per-period working-capital absorption or release, from the same published history. Positive values are working-capital build; negative values are release.
The setup & the reality
The latest result is checked against what the prior briefing said to watch.
Historical setup
From RUA revenue rose 490.6% but the business remains deeply cash-negative
No formal targets were provided and no forward guidance was quantified. The release notes strong momentum expected to continue into FY26 and references expanded markets including Germany and the UK. The H2 revenue run-rate of NZD 1.2m, if sustained, would imply an annualised revenue approaching NZD 2.4m, though that would still fall well short of the level needed to approach cash breakeven given the current cost base.
The central uncertainty is whether revenue growth can outpace cash consumption quickly enough to avoid further dilutive capital raises. The trajectory is improving, but the gap between revenue and cash breakeven remains large relative to available liquidity.
Open questions
This briefing cannot assess pipeline optionality, regulatory approval timelines, or the probability of achieving cash-flow breakeven without disclosed cost-structure detail and forward revenue commitments.
Archive
Every published Annolyse briefing for this company appears here in reverse chronological order.
HY26 · Released 27 February 2026
A 4.5x step-up in debt funded most of the cash uplift while total assets sit below the supplied historical range.
FY25 · Released 1 September 2025
Strong commercial momentum cut the loss before tax by 74.8%, yet cash fell to NZD 0.2m and operating outflows persist, making runway the central
HY24 · Released 29 February 2024
Management writes off a prior acquisition that failed to deliver, leaving a $1.0m cash buffer and ongoing operating burn.
FY23 · Released 29 August 2023
Headline revenue of $6.5m is dominated by fair value gains on contingent consideration; commercial revenue remains immaterial against ongoing burn.
HY23 · Released 28 February 2023
Non-cash items drove the swing to NPAT while operating cash outflow held near prior levels and the cash balance fell 24.5%.
FY22 · Released 29 August 2022
First product sales arrived but losses widened materially, leaving only months of cash at the current operating burn rate.
HY22 · Released 25 February 2022
Headline cash fell from $19.2m to $2.3m as Rua moves to commercialisation, with the loss widening only modestly.
Get the next Rua Bioscience result briefing and five-year history updates by email.